TransVoyant, an Alexandria, VA-based provider of an intelligent supply chain execution platform, closed its first strategic growth equity financing co-led by Merck Global Health Innovation Fund (MGHIF) and P74 Ventures.
The round brought the total funding to more than $30m.
The company intends to use the funds to scale to reach new customers and expand use cases across the life sciences value chain.
Founded in 2012 and Dennis Groseclose, CEO, TransVoyant is a global intelligent supply chain execution platform which analyzes billions of data points across thousands of sources, continually combining internal data with information from ecosystem partners, IoT devices and OT systems to proactively offer timely insights on past, present, and future supply chain behavior.
Key life sciences customers include Merck, McKesson, United Healthcare, Convatec and DSM.
FinSMEs
14/12/2022
Merck Global Health Innovation Fund (MGHIF) is a growth investor partnering with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. With access to Merck’s (known as MSD outside United States and Canada) expertise in clinical development, commercialization, supply chain management, and regulatory compliance, MGHIF is building an ecosystem of companies creating integrated health care solutions. MGHIF has distinguished itself as a leader in digital health by using its $500 million evergreen fund to invest more than $1 billion in more than 70 emerging companies, generating more than $7 billion in exits. For more information, visit www.merckghifund.com or www.merck.com and connect with Merck on Twitter, Facebook, Instagram, YouTube and LinkedIn.